Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Earnings Call Transcript: Key Takeaways

Q2 FY27 revenue ₹2,820 Cr (+24%) and PAT ₹325 Cr (+29%) were strong. FY27 revenue growth guidance raised to above 20%. Net debt rose ₹263 Cr on acquisition payouts. FY28 guidance withheld.

Call

Guides 20% growth

Emcure Pharmaceuticals Investor Presentation: Key Takeaways

Q2FY27 revenue INR 28,205 Mn (+24.3% YoY), EBITDA INR 5,748 Mn (20.4% margin, +103 bps), PAT INR 3,251 Mn (+29.3%). International-led growth; net debt rose on acquisition payments.

Emcure Pharmaceuticals Q2 FY27 Results: Net Profit ₹325.1 Cr, Up 29.3% YoY

Emcure Pharmaceuticals Ltd reported revenue from operations of ₹2,820 Cr (+24.3% YoY) and net profit of ₹325.1 Cr (+29.3% YoY) for Q2 FY27.

Key figure

Net profit ₹325.1 Cr · +29.3% YoY

Emcure Pharmaceuticals Other Announcement

Emcure Pharmaceuticals submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance disclosure under SEBI.

Emcure Pharmaceuticals Board Meeting Date

Emcure Pharmaceuticals will hold a board meeting on November 03, 2026, to consider and approve the company's standalone and consolidated financial results for the quarter.